UBE2T and breast cancer: Even though FANCT did not have the highest mutational rate in breast invasive carcinoma NOS, it had the highest mutation rate in breast cancer overall (Table 1), likely due to its relatively higher mutational rates in breast mixed ductal and lobular carcinoma (25%), neoplasms (19%), and breast invasive ductal carcinoma (15.5%).